Rare cases of Guillain-Barr é syndrome after COVID-19 vaccination, Germany, December 2020 to August 2021
ConclusionThree and four times more GBS cases than expected were reported after vaccination with Vaxzevria and COVID-19 Vaccine Janssen, respectively, therefore GBS might be an adverse event of vector-based vaccines. Bifacial paresis was more common in cases with GBS following vaccination with vector-based than mRNA COVID-19 vaccines. (Source: Eurosurveillance)
Source: Eurosurveillance - June 15, 2023 Category: Infectious Diseases Authors: Helmar C Lehmann, Doris Oberle, Brigitte Keller-Stanislawski, Thorsten Rieck and Renz Streit Source Type: research
Erratum for Euro Surveill. 2023;28(22)
(Source: Eurosurveillance)
Source: Eurosurveillance - June 8, 2023 Category: Infectious Diseases Authors: Eurosurveillance editorial team Source Type: research
Lessons from a recent multicountry iatrogenic botulism outbreak
(Source: Eurosurveillance)
Source: Eurosurveillance - June 8, 2023 Category: Infectious Diseases Authors: Fabrizio Anniballi Source Type: research
A large travel-associated outbreak of iatrogenic botulism in four European countries following intragastric botulinum neurotoxin injections for weight reduction, T ürkiye, February to March 2023
In March 2023, 34 associated cases of iatrogenic botulism were detected in Germany (30 cases), Switzerland (two cases), Austria (one case), and France (one case). An alert was rapidly disseminated via European Union networks and communication platforms (Food- and Waterborne Diseases and Zoonoses Network, EpiPulse, Early Warning and Response System) and the International Health Regulation mechanism; the outbreak was investigated in a European collaboration. We traced sources of the botulism outbreak to treatment of weight loss in Türkiye, involving intragastric injections of botulinum neurotoxin. Cases were traced usin...
Source: Eurosurveillance - June 8, 2023 Category: Infectious Diseases Authors: Martin Bernhard Dorner, Hendrik Wilking, Martin Skiba, Laura Wilk, Maximilian Steinberg, Sylvia Worbs, Sabahat Çeken, Sedat Kaygusuz, Stéphanie Simon, François Becher, Agata Mikolajewska, Christian Kornschober, Timo Bütler, Nathalie Jourdan-Da-Silva, Source Type: research
Establishing severe acute respiratory infection (SARI) surveillance in a sentinel hospital, Ireland, 2021 to 2022
ConclusionWe successfully established SARI surveillance as part of E-SARI-NET. Expansion to additional sentinel sites is planned following formal evaluation of the existing system. SARI surveillance requires multidisciplinary collaboration, automated data collection where possible, and dedicated personnel resources, including for specimen management. (Source: Eurosurveillance)
Source: Eurosurveillance - June 8, 2023 Category: Infectious Diseases Authors: Melissa Brady, Roisin Duffy, Lisa Domegan, Abigail Salmon, Binita Maharjan, Cathal O'Broin, Charlene Bennett, James Christle, Jeff Connell, Laura Feeney, Nadra Nurdin, Patrick Mallon, Peter Doran, Rosa McNamara, Sarah O'Grady, Sinead McDermott, Naomi Pett Source Type: research
Developing evidence-informed indicators to monitor HIV pre-exposure prophylaxis programmes across EU/EEA countries: a multi-stakeholder consensus
We present a set of indicators, structured along relevant steps of an adapted PrEP care continuum, and offer a prioritisation based on the degree of consensus among the expert panel. We distinguish between‘core’ indicators deemed essential for any PrEP programme in the EU/EEA, vs‘supplementary’ and‘optional’ indicators that provide meaningful data, yet where experts evaluated their feasibility for data collection and reporting as very context-dependent. By combining a standardised approach with strategic opportunities for adaptation and complementary research, this monitoring framework w...
Source: Eurosurveillance - June 8, 2023 Category: Infectious Diseases Authors: Jef Vanhamel, Eline Wijstma, Jessika Deblonde, Marie Laga, Bea Vuylsteke, Christiana N östlinger and Teymur Noori Source Type: research
ECDC Director vacancy now open
(Source: Eurosurveillance)
Source: Eurosurveillance - June 1, 2023 Category: Infectious Diseases Authors: Eurosurveillance editorial team Source Type: research
Severe and fatal neonatal infections linked to a new variant of echovirus 11, France, July 2022 to April 2023
We report nine severe neonatal infections caused by a new variant of echovirus 11. All were male, eight were twins. At illness onset, they were 3–5 days-old and had severe sepsis and liver failure. This new variant, detected in France since April 2022, is still circulating and has caused more fatal neonatal enterovirus infections in 2022 and 2023 (8/496; 1.6%, seven associated with echovirus 11) compared with 2016 to 2021 (7/1,774; 0.4%). National and international alerts are warranted. (Source: Eurosurveillance)
Source: Eurosurveillance - June 1, 2023 Category: Infectious Diseases Authors: Mathilde Grapin, Audrey Mirand, Didier Pinquier, Aur élie Basset, Matthieu Bendavid, Maxime Bisseux, Marion Jeannoël, Bérengère Kireche, Manoelle Kossorotoff, Anne-Sophie L’Honneur, Lila Robin, Yves Ville, Sylvain Renolleau, Véronique Lemee, Pierre Source Type: research
Towards One Health surveillance of antibiotic resistance: characterisation and mapping of existing programmes in humans, animals, food and the environment in France, 2021
ConclusionThe French surveillance system appears extensive but has gaps and is highly fragmented. We believe our mapping will interest policymakers and surveillance stakeholders. Our methodology may inspire other countries considering One Health surveillance of ABR. (Source: Eurosurveillance)
Source: Eurosurveillance - June 1, 2023 Category: Infectious Diseases Authors: Lucie Collineau, Cl émence Bourély, Léo Rousset, Anne Berger-Carbonne, Marie-Cécile Ploy, Céline Pulcini and Mélanie Colomb-Cotinat Source Type: research
Assessing the robustness of COVID-19 vaccine efficacy trials: systematic review and meta-analysis, January 2023
ConclusionsThis was the largest study on trial robustness to date. Robustness of COVID-19 VE trials increased with sample size and varied considerably across several other important trial characteristics. The FI and FQ are valuable complementary parameters for the interpretation of trial results and should be reported alongside established trial outcome measures. (Source: Eurosurveillance)
Source: Eurosurveillance - June 1, 2023 Category: Infectious Diseases Authors: Thi Ngoc Anh Hoang, Ha-Linh Quach, Van Ngoc Hoang, Van Thien Tran, Quang Thai Pham and Florian Vogt Source Type: research
Emergence, spread and characterisation of the SARS-CoV-2 variant B.1.640 circulating in France, October 2021 to February 2022
ConclusionEven though B.1.640 did not outcompete the Delta variant, its importation and continuous low-level spread raised concerns regarding its public health impact. The investigations informed public health decisions during the time that B.1.640 was circulating. (Source: Eurosurveillance)
Source: Eurosurveillance - June 1, 2023 Category: Infectious Diseases Authors: Gwenola Picard, Lucie Fournier, Anna Maisa, Claire Grolhier, Souhaila Chent, Caroline Huchet-Kervalla, Jeanne Sudour, Ma ël Pretet, Laurence Josset, Sylvie Behillil, Justine Schaeffer, Laboratory group and COVID-19 Investigation Group Source Type: research
Author ’s correction for Euro Surveill. 2023;28(18)
(Source: Eurosurveillance)
Source: Eurosurveillance - May 25, 2023 Category: Infectious Diseases Authors: Eurosurveillance editorial team Source Type: research
Interim 2022/23 influenza vaccine effectiveness: six European studies, October 2022 to January 2023
ConclusionsInterim results from six European studies during the 2022/23 influenza season indicate a ≥ 27% and ≥ 50% reduction in disease occurrence among all-age influenza vaccine recipients for influenza A and B, respectively, with higher reductions among children. Genetic virus characterisation results and end-of-season VE estimates will contribute to greater understanding of differences in influenza (sub)type-specific results across studies. (Source: Eurosurveillance)
Source: Eurosurveillance - May 25, 2023 Category: Infectious Diseases Authors: Esther Kissling, Marine Maurel, Hanne-Dorthe Emborg, Heather Whitaker, Jim McMenamin, Jennifer Howard, Ramona Trebbien, Conall Watson, Beth Findlay, Francisco Pozo, Amanda Bolt Botnen, Ciaran Harvey, Angela Rose and European IVE group Source Type: research
Dynamics of SARS-CoV-2 seroassay sensitivity: a systematic review and modelling study
ConclusionsSeroassay sensitivity decay depends on assay characteristics, and for some types of assays, it can make manufacturer specifications highly unreliable. We provide a tool to correct for this phenomenon and to assess the risk of decay for a given assay. Our analysis can guide the design and interpretation of serosurveys for SARS-CoV-2 and other pathogens and quantify systematic biases in the existing serology literature. (Source: Eurosurveillance)
Source: Eurosurveillance - May 25, 2023 Category: Infectious Diseases Authors: Nana Owusu-Boaitey, Timothy W Russell, Gideon Meyerowitz-Katz, Andrew T Levin and Daniel Herrera-Esposito Source Type: research
Comprehensive surveillance of acute respiratory infections during the COVID-19 pandemic: a methodological approach using sentinel networks, Castilla y Le ón, Spain, January 2020 to May 2022
ConclusionExtracting data from electronic medical records reported by trained professionals, combined with a standardised microbiological information system, is a feasible and useful method to adapt influenza sentinel reports to comprehensive ARI surveillance in the post-COVID-19 era. (Source: Eurosurveillance)
Source: Eurosurveillance - May 25, 2023 Category: Infectious Diseases Authors: Tom ás Vega-Alonso, Jose Eugenio Lozano-Alonso, Ana Ordax-Díez and on behalf of the VIGIRA Research Group Source Type: research
